
Sidley represented Starna Therapeutics Co., Ltd., a China-based biotechnology company developing innovative therapeutics using proprietary RNA delivery technologies, in an exclusive licensing agreement with Pfizer Inc. valued at up to approximately US$2.6 billion, plus royalties. The agreement includes a US$330 million upfront payment and up to US$2.3 billion in potential milestone payments. Under the agreement, Pfizer will receive exclusive rights to develop, manufacture, and commercialize three of Starna’s investigational in vivo chimeric antigen receptor T-cell (CAR-T) programs outside Greater China. The collaboration also provides Pfizer with rights to use Starna’s proprietary technology in inflammation, immunology, and oncology, supporting the development of potential new therapies for autoimmune diseases and cancer.
The Sidley team was led by Lila Hope and Jennifer Raab (Technology and Life Sciences Transactions), and included Yuhan Wu (Technology and Life Sciences Transactions).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record

